Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
9.60
-0.28 (-2.83%)
Nov 16, 2026, 9:35 AM EST - Market open

Biodesix Statistics

Total Valuation

Biodesix has a market cap or net worth of $106.45 million. The enterprise value is $150.48 million.

Market Cap106.45M
Enterprise Value 150.48M

Important Dates

The last earnings date was Thursday, November 5, 2026, after market close.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Biodesix has 11.09 million shares outstanding. The number of shares has increased by 31.30% in one year.

Current Share Class 11.09M
Shares Outstanding 11.09M
Shares Change (YoY) +31.30%
Shares Change (QoQ) +3.54%
Owned by Insiders (%) 39.78%
Owned by Institutions (%) 29.68%
Float 5.41M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.04
Forward PS 0.93
PB Ratio 12.59
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.46
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.96, with a Debt / Equity ratio of 8.35.

Current Ratio 2.96
Quick Ratio 2.63
Debt / Equity 8.35
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -2.45

Financial Efficiency

Return on equity (ROE) is -778.89% and return on invested capital (ROIC) is -16.13%.

Return on Equity (ROE) -778.89%
Return on Assets (ROA) -13.45%
Return on Invested Capital (ROIC) -16.13%
Return on Capital Employed (ROCE) -24.66%
Weighted Average Cost of Capital (WACC) 8.13%
Revenue Per Employee $315,006
Profits Per Employee -$81,072
Employee Count334
Asset Turnover 1.15
Inventory Turnover 14.28

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +27.50% in the last 52 weeks. The beta is 0.63, so Biodesix's price volatility has been lower than the market average.

Beta (5Y) 0.63
52-Week Price Change +27.50%
50-Day Moving Average 23.58
200-Day Moving Average 18.89
Relative Strength Index (RSI) 25.60
Average Volume (20 Days) 280,082

Short Selling Information

The latest short interest is 210,018, so 1.89% of the outstanding shares have been sold short.

Short Interest 210,018
Short Previous Month 209,504
Short % of Shares Out 1.89%
Short % of Float 3.89%
Short Ratio (days to cover) 2.28

Income Statement

In the last 12 months, Biodesix had revenue of $105.21 million and -$27.08 million in losses. Loss per share was -$2.80.

Revenue105.21M
Gross Profit 86.65M
Operating Income -19.65M
Pretax Income -27.08M
Net Income -27.08M
EBITDA -14.08M
EBIT -19.65M
Loss Per Share -$2.80
Full Income Statement

Balance Sheet

The company has $28.41 million in cash and $72.44 million in debt, with a net cash position of -$44.03 million or -$3.97 per share.

Cash & Cash Equivalents 28.41M
Total Debt 72.44M
Net Cash -44.03M
Net Cash Per Share -$3.97
Equity (Book Value) 8.68M
Book Value Per Share 0.78
Working Capital 27.89M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$18.16 million and capital expenditures -$919,000, giving a free cash flow of -$19.07 million.

Operating Cash Flow -18.16M
Capital Expenditures -919,000
Depreciation & Amortization 5.57M
Net Borrowing -11,000
Free Cash Flow -19.07M
FCF Per Share -$1.72
Full Cash Flow Statement

Margins

Gross margin is 82.36%, with operating and profit margins of -18.68% and -25.74%.

Gross Margin 82.36%
Operating Margin -18.68%
Pretax Margin -25.74%
Profit Margin -25.74%
EBITDA Margin -13.38%
EBIT Margin -18.68%
FCF Margin n/a

Dividends & Yields

Biodesix does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -31.30%
Shareholder Yield -31.30%
Earnings Yield -29.16%
FCF Yield -17.41%

Analyst Forecast

The average price target for Biodesix is $32.17, which is 235.10% higher than the current price. The consensus rating is "Strong Buy".

Price Target $32.17
Price Target Difference 235.10%
Analyst Consensus Strong Buy
Analyst Count 7
Revenue Growth Forecast (3Y) 19.38%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date Sep 15, 2025
Split Type Reverse
Split Ratio 1:20

Scores

Biodesix has an Altman Z-Score of -5.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -5.96
Piotroski F-Score 4